ALX Oncology won’t seek approval for CD47 drug in gastric cancer; Korro Bio’s...
Plus, news about Cognition Therapeutics, Sagimet Biosciences, BeiGene, Hikma and Rallybio: ALX Oncology won’t pursue approval in gastric cancer: The company had been aiming to get its CD47-targeting...
View ArticleBristol Myers' $40B US investment; Shionogi to buy Japanese drugmaker
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Bristol Myers Squibb said it is committing $40 billion over the next...
View ArticleVerastem wins first FDA approval for ovarian cancer therapy
Boston-based Verastem Oncology on Thursday won accelerated approval from the FDA for Avmapki Fakzynja as a second-line treatment for adult patients with KRAS-mutated recurrent low-grade serous ovarian...
View ArticleGSK awaits Nucala decision after FDA target date passes
The FDA is still reviewing a label expansion for GSK’s respiratory drug Nucala in chronic obstructive pulmonary disease despite the May 7 target date for a decision, the company confirmed to ...
View ArticleAstraZeneca loses appeals court fight over IRA drug price negotiations
AstraZeneca lost its challenge to Medicare drug price negotiations in the first appeals court ruling on the merits of the Biden-era program. The decision, issued Thursday by the US Court of Appeals ...
View ArticleAI-focused biotech insitro cuts 22% of staff, citing 'tumultuous market'
The AI-focused biotech insitro has laid off 22% of its workforce, the company said in a Thursday statement. Founded in 2018 by CEO Daphne Koller, a leading computer scientist at Stanford University,...
View ArticleIllumina forecasts $85M in tariff costs, decrease in China sales
Illumina estimates about $85 million in costs this year related to tariffs on its DNA sequencing products, the company said Thursday during its quarterly earnings report. In addition, it expects China...
View ArticleTakeda announces handful of pipeline cuts in effort to ‘pivot resources’
Takeda revealed a handful of pipeline cuts in its fourth-quarter earnings results on Thursday, as the company focuses its attention on six late-stage programs it says could deliver billions of dollars...
View ArticleIllumina confirms SEC has closed investigation into $8B Grail deal
Illumina on Thursday said the SEC has closed its investigation into the company's $8 billion purchase of Grail and doesn't intend to pursue enforcement action, confirming Endpoints News' reporting...
View ArticleAI biotech Insilico Medicine goes for third attempt at Hong Kong IPO
Insilico Medicine is hoping to ride a recent wave of momentum for biotech startups on the Hong Kong Stock Exchange. The biotech, headquartered in Cambridge, MA, filed for ...
View ArticleCorvus' Phase 1 atopic dermatitis data prompt stock rally
Corvus Pharmaceuticals reported new Phase 1 data in atopic dermatitis that sent its stock price {$CRVS} up by as much as 35% premarket Friday. The results come from three cohorts of ...
View ArticleLilly shuffles key executive positions; Mikael Dolsten takes another...
→ Eli Lilly is making some adjustments to its team: Patrik Jonsson and Ilya Yuffa will trade places as Jonsson becomes president of Lilly International, while Yuffa succeeds Jonsson with an ...
View ArticleIntroducing the new Endpoints profile experience
We’ve got some exciting upgrades coming to the Endpoints platform this year. Today, we’re launching the first step — a new profile experience — which will serve as a single place to access and manage...
View ArticleLonza says its US-based sites are in high demand as pharma tariffs near
Lonza said on Friday it does not expect any “material financial impact” from current and potential pharma-specific tariffs, as the Swiss CDMO fields inquiries for its US-based facilities ...
View ArticleRevolution’s KRAS drugs appear competitive in several lung cancer settings
Revolution Medicines revealed new data that suggest its closely watched KRAS-targeting cancer programs could be highly competitive with similar therapies already on the market. The biotech’s shares...
View ArticleAstraZeneca reports Phase 3 win for Imfinzi; Roche to build new manufacturing...
Plus, news about Sanofi, IGM Biosciences, Eli Lilly, Purdue University, Minghui, Qilu, Sirius Therapeutics, Keros Therapeutics, Palatin and Leo Pharma: 💉AstraZeneca touts Imfinzi Phase 3 win in...
View ArticleChronic care startup Omada Health files to go public
Virtual diabetes and chronic care startup Omada Health filed to go public on Friday, making it the second digital health company to do so this year as the sector shows signs of picking up after ...
View ArticleMakary names Vinay Prasad CBER chief; Q1 earnings report; More on “Most...
Welcome back to Endpoints Weekly — thanks for starting your Saturday with us. It was a busy week in the biopharma world. FDA Commissioner Marty Makary picked a new CBER chief to replace Peter Marks,...
View ArticleTrump confirms 'most favored nation' drug price plans
President Donald Trump said he'll take executive action to have the US pay no more than other countries for drugs, a move that would expand price controls and is almost certain to generate strident...
View Article